Jérôme Mouroux

ORCID: 0000-0003-0877-4679
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Diagnosis and Treatment
  • Pleural and Pulmonary Diseases
  • Lung Cancer Treatments and Mutations
  • Medical Imaging and Pathology Studies
  • Esophageal and GI Pathology
  • Tracheal and airway disorders
  • Congenital Diaphragmatic Hernia Studies
  • Occupational and environmental lung diseases
  • Cancer Cells and Metastasis
  • Myasthenia Gravis and Thymoma
  • Esophageal Cancer Research and Treatment
  • Metastasis and carcinoma case studies
  • Cancer Genomics and Diagnostics
  • Cancer Diagnosis and Treatment
  • Trauma Management and Diagnosis
  • Cancer Immunotherapy and Biomarkers
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Colorectal Cancer Treatments and Studies
  • Respiratory Support and Mechanisms
  • Lung Cancer Research Studies
  • Sarcoma Diagnosis and Treatment
  • Cardiac, Anesthesia and Surgical Outcomes
  • Cardiac tumors and thrombi
  • Soft tissue tumor case studies
  • Genetic factors in colorectal cancer

Inserm
2010-2023

Hôpital Pasteur
2012-2023

Institut de Recherche sur le Cancer et le Vieillissement de Nice
2012-2023

Université Côte d'Azur
2010-2023

Centre National de la Recherche Scientifique
2013-2023

Observatoire de la Côte d’Azur
2023

Centre Hospitalier Universitaire de Nice
2011-2020

Creative Commons
2018

The Affiliated Yongchuan Hospital of Chongqing Medical University
2018

Chongqing Medical University
2018

Chronic obstructive pulmonary disease (COPD) is a risk factor for lung cancer. Migration of circulating tumor cells (CTCs) into the blood stream an early event that occurs during carcinogenesis. We aimed to examine presence CTCs in complement CT-scan COPD patients without clinically detectable cancer as first step identify new marker diagnosis. The was examined by ISET filtration-enrichment technique, 245 subjects cancer, including 168 (68.6%) patients, and 77 (31.4%), 42 control smokers 35...

10.1371/journal.pone.0111597 article EN cc-by PLoS ONE 2014-10-31

Pathologic TNM staging is currently the best prognostic factor for non-small cell lung carcinoma (NSCLC). However, even in early-stage NSCLC, recurrence rates after surgery range from 25% to 50%. The preoperative detection of circulating tumor cells (CTC) could be useful tailor new therapeutic strategies NSCLC. We assessed presence CTC NSCLC patients undergoing surgery, using cytologic analyses, their isolation by size epithelial (ISET method). and number CTCs were considered correlated with...

10.1158/1078-0432.ccr-10-0445 article EN Clinical Cancer Research 2010-11-24

Abstract Comparison of the efficacy different enrichment methods for detection circulating tumor cells (CTCs) before radical surgery is lacking in non‐small‐cell lung carcinoma (NSCLC) patients. Detection and enumeration CTCs 210 consecutive patients undergoing NSCLC were evaluated with CellSearch Assay™ (CS), using Epithelial Cell Kit, by isolation size epithelial (ISET) method, double immunolabeling anti‐cytokeratin anti‐vimentin antibodies. detected 144 (69%) CS and/or ISET 104 (50%) 82...

10.1002/ijc.25819 article EN International Journal of Cancer 2010-12-02

Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with rising incidence and challenging clinical management. Through a large series of whole-genome sequencing data, integrated transcriptomic epigenomic data using multiomics factor analysis, we demonstrate that the current World Health Organization classification only accounts for up to 10% interpatient molecular differences. Instead, MESOMICS project paves way morphomolecular MPM based on four dimensions: ploidy, tumor...

10.1038/s41588-023-01321-1 article EN cc-by Nature Genetics 2023-03-16

Carbonic anhydrase IX (CAIX) is an enzyme upregulated by hypoxia during tumour development and progression. This study was conducted to assess if the expression of CAIX in tissue and/or plasma can be a prognostic factor patients with non-small cell lung cancer (NSCLC). Tissue microarrays containing 555 NSCLC samples were generated for quantification expression. The level determined ELISA 209 these 58 healthy individuals. immunostaining levels correlated clinicopathological factors patient...

10.1038/sj.bjc.6605690 article EN cc-by-nc-sa British Journal of Cancer 2010-05-01

The diagnosis of non-small cell lung carcinoma (NSCLC) at an early stage, as well better prediction outcome remains clinically challenging due to the lack specific and robust non-invasive markers. discovery microRNAs (miRNAs), particularly those found in bloodstream, has opened up new perspectives for tumor prognosis. aim our study was determine whether expression profiles miRNAs plasma could accurately discriminate between NSCLC patients controls, they are able predict prognosis resectable...

10.1371/journal.pone.0054596 article EN cc-by PLoS ONE 2013-01-16

Abstract BACKGROUND: The role of the interaction between tumor cells and inflammatory in nonsmall cell lung carcinoma (NSCLC) is unclear. In this study, authors assessed prognostic impact intratumoral cluster differentiation 66b (carcinoembryonic antigen‐related adhesion molecule 8 [CD66b])‐positive neutrophils CD66b‐positive neutrophil‐to‐cluster (cell surface antigen T8 [CD8])‐positive lymphocytes (the neutrophil‐to‐CD8‐positive lymphocyte ratio [iNTR]) patients with resectable NSCLC....

10.1002/cncr.26456 article EN Cancer 2011-08-25

Nutritional assessment is not included yet as a major recommendation in lung cancer guidelines. The purpose of this study was thus to assess the influence on surgical outcome nutritional status patients with primary undergoing lobectomy. We queried Epithor, national clinical database French Society Thoracic and Cardiovascular Surgery, identified retrospective cohort 19 635 having undergone lobectomy for years 2005–11. Their categorized according WHO definition: underweight (BMI < 18.5): 857...

10.1093/ejcts/ezt452 article EN European Journal of Cardio-Thoracic Surgery 2013-09-23

Recurrence rates after surgery for non-small cell lung cancer (NSCLC) range from 25 to 50% and 5-year survival is only 60-70%. Because no biomarkers are predictive of recurrence or the onset metastasis, pathological TNM (pTNM) staging currently best prognostic factor. Consequently, preoperative detection circulating tumour cells (CTCs) might be useful in tailoring therapy. The aim this study was characterize morphologically any non-haematological (CNHCs) patients undergoing NSCLC using...

10.1111/j.1365-2303.2010.00835.x article EN Cytopathology 2011-01-06

Detection of circulating tumor cells (CTCs) morphologically may be a promising new approach in clinical oncology. We tested the reliability cytomorphologic to identify CTCs: 808 blood samples from patients with benign and malignant diseases healthy volunteers were examined using isolation by size epithelial cell (ISET) method. Cells having nonhematologic features (so-called [CNHCs]) classified into 3 categories: CNHCs features, uncertain features. found 11.1% 48.9% nonmalignant pathologies,...

10.1309/ajcp9x8ozbeiqvvi article EN American Journal of Clinical Pathology 2010-12-20

The value of magnetic resonance (MR) imaging and the roles various pulse sequences contrast medium enhancement in detection chest wall invasion were evaluated 34 patients with primary bronchogenic carcinoma. Results correlated clinical data computed tomographic studies. MR criteria parietal included signal intensity identical to that tumor on T1-weighted images, intraparietal hyperintense T2-weighted gadoterate meglumine administration. Twenty had involvement, was positive 18 20...

10.1148/radiology.187.1.8451432 article EN Radiology 1993-04-01

Sarcomatoid carcinomas (SC) of the lung are uncommon malignant tumors composed carcinomatous and sarcomatous cell components characterized by a more aggressive outcome than other histological subtypes nonsmall cancer (NSCLC). Although epidermal growth factor receptor (EGFR)-targeted therapies have emerged as promising therapeutic approach in patients with advanced typical NSCLC such adenocarcinoma, potential clinical activity these drugs SC is still unknown. To investigate this point, we...

10.1002/ijc.24610 article EN International Journal of Cancer 2009-06-02

The pattern of protein expression in tumors is under the influence nutrient stress, hypoxia and low pH, which determines survival neoplastic cells development tumors. Carbonic anhydrase XII (CAXII) a transmembrane enzyme that catalyzes reversible hydration cell-generated carbon dioxide into protons bicarbonate. Hypoxic conditions activate its transcription translation enhanced often present several types aim our study was to assess prognostic significance CAXII tumor tissues patients with...

10.1002/ijc.25491 article EN International Journal of Cancer 2010-06-02

In Brief Objectives: To assess the impact of neoadjuvant chemoradiotherapy (NCRT) on anastomotic leakage (AL) and other postoperative outcomes after esophageal cancer (EC) resection. Background: Conflicting data have emerged from randomized studies regarding NCRT AL. Methods: Among 2944 consecutive patients operated for EC between 2000 2010 in 30 European centers, treated by surgery (n = 593) were compared with those primary 1487). Multivariable analyses propensity score matching used to...

10.1097/sla.0000000000000955 article EN Annals of Surgery 2014-10-07

With the ongoing need to improve therapy for non-small cell lung cancer (NSCLC) there has been increasing interest in developing reliable preclinical models test novel therapeutics. Patient-derived tumor xenografts (PDX) are considered be interesting candidates. However, establishment of such model systems requires highly specialized research facilities and introduces logistic challenges. We aimed establish an extensive well-characterized panel NSCLC xenograft context a long-distance network...

10.1002/cam4.357 article EN cc-by Cancer Medicine 2014-12-03
Sheraz R. Markar Caroline Gronnier Arnaud Pasquer Alain Duhamel Hélène Beal and 95 more Jérémie Thereaux Johan Gagnière Gil Lebreton Cécile Brigand B. Meunier Denis Collet C. Mariette Abdennahceur Dhahri Delphine Lignier Cyril Cossé Jean-Marc Regimbeau Denis Collet Magalie Cabau Jacques Jougon Bogdan Badic P Lozac’h Jean Pierre Bail Serge Cappeliez Issam El Nakadi Gil Lebreton Arnaud Alvès Renaud Flamein Denis Pezet Federica Pipitone Bogdan Stan-Iuga Nicolas Contival Eric Pappalardo Simon Msika Styliani Mantziari Nicolas Demartines Flora Hec Marguerite Vanderbeken Williams Tessier Nicolas Briez Fabien Fredon A Gainant Muriel Mathonnet Jean Marc Bigourdan Salim Mezoughi Christian Ducerf J Baulieux Jean‐Yves Mabrut Oussama Baraket Gilles Poncet Mustapha Adham D. Vaudoyer Peggy Jourdan Enfer Laurent Villeneuve Olivier Gléhen Thibault Coste Jean-Michel Fabre Frédéric Marchal Romain Frisoni Ahmet Ayav Laurent Brunaud Laurent Bresler Charlotte Cohen Olivier Aze Nicolas Vénissac Daniel Pop Jérôme Mouroux Ion Donici Michel Prudhomme Emanuele Felli Stéphanie Lisunfui M. Seman Gaëlle Petit Mehdi Karoui Christophe Tresallet F. Ménégaux Jean-Christophe Vaillant L Hannoun Brice Malgras Denis Lantuas Karine Pautrat Marc Pocard Patrice Valleur Najim Chafaı̈ Pierre Balladur Magalie Lefrançois Yann Parc François Paye Emmanuel Tiret Marius Nedelcu Letizia Laface T Perniceni Brice Gayet B. Meunier Alexandre Filipello Jack Porcheron Olivier Tiffet Noémie Kamlet Rodrigue Chemaly Amandine Klipfel Patrick Pessaux

10.1016/j.ejca.2015.11.024 article EN European Journal of Cancer 2016-01-22
Coming Soon ...